JMP Securities Maintains Market Outperform on Syros Pharmaceuticals, Lowers Price Target to $4
Portfolio Pulse from Benzinga Newsdesk
JMP Securities analyst Jason Butler maintains a Market Outperform rating on Syros Pharmaceuticals (NASDAQ:SYRS) but lowers the price target from $12 to $4.
August 13, 2024 | 11:56 am
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
JMP Securities has maintained its Market Outperform rating on Syros Pharmaceuticals but significantly lowered the price target from $12 to $4.
The significant reduction in the price target from $12 to $4 suggests a more cautious outlook on Syros Pharmaceuticals' future performance, which could negatively impact investor sentiment and the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100